Several preclinical studies have found that an adenovirus vector expressing a heterologous omicron strain SARS-CoV-2 spike antigen when given as a mucosal boosting vaccine induces both robust mucosal IgA and IgG and systemic IgG specific for the omicron strain, which was associated with improved protection from infection (Gagne et al., 2024; McMahan et al., 2024; Xing et al., 2024), thus suggesting that mucosal boosting might simultaneously induce desirable mucosal immunity and also bypass a detrimental imprint toward priming antigens. Here, CD79A is linked to infection.